Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 1/2 1

Status

Completed 5

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Imatinib Mesylate × Clear all
NCT00401024 2018-06-28

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
3 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00354068 2013-03-28

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Duke University

Phase 1 Completed
65 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00613132 2013-02-20

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Duke University

Phase 1 Completed
78 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡